Jentadueto Lawsuit | 2025 Latest Updates

If you or a loved one experienced pancreatic cancer, thyroid cancer, or bullous pemphigoid following the use of Jentadueto for type 2 diabetes, you may be entitled to pursue compensation.

At Schmidt & Clark, we are dedicated to helping individuals who have suffered due to dangerous pharmaceutical drugs.

Our experienced legal team is here to guide you through the process and fight for the compensation you deserve. Contact Schmidt & Clark today for a free, no-obligation consultation.

Jentadueto Lawsuit Overview

The Jentadueto lawsuits center on serious health complications allegedly caused by this type 2 diabetes medication.

The primary allegations against the manufacturer involve failure to adequately warn patients and healthcare providers about the increased risk of developing pancreatic cancer, thyroid cancer, and bullous pemphigoid associated with the drug.

Additionally, the FDA has received reports of rhabdomyolysis in patients taking Jentadueto and other DPP-4 inhibitors.

These safety concerns have prompted multiple studies examining the causal link between incretin mimetic drugs like Jentadueto and various serious adverse effects, leading to legal action by affected patients.

What’s the Problem?

The potential side effects of incretin mimetic drugs like Jentadueto have recently become a subject of serious concern among individuals with type 2 diabetes.

These concerns came in response to several studies which identified a casual link between incretin mimetics and cancer of the pancreas and thyroid.

According to a study published in the medical journal Gastroenterology, the use of Byetta (another incretin mimetic in the same class as Jentadueto) increased the risk of pancreatitis by six times compared to other types of diabetes drugs.

If left untreated, pancreatitis has the potential to lead to full-blown pancreatic cancer. The study also raised caution about the drugs’ ability to cause thyroid cancer. If you or a loved one has developed cancer after using Jentadueto, you may qualify to participate in a Jentadueto Lawsuit.

Latest Jentadueto Lawsuit Updates

December 1, 2017

– FDA announced it was investigating reports of rhabdomyolysis, a serious muscle condition, in patients taking Jentadueto and other DPP-4 inhibitors [1].

October 2016 – FDA required manufacturers of DPP-4 inhibitors, including Jentadueto, to add warnings about bullous pemphigoid, a rare skin disease that causes severe blistering, to their product labeling after receiving multiple reports of the condition.

According to data from clinical studies, patients taking incretin mimetic drugs like Jentadueto have a six times higher risk of developing pancreatitis compared to those taking other diabetes medications [2].

Pancreatitis is a known risk factor for developing pancreatic cancer, which has one of the lowest survival rates among all cancer types, with a five-year survival rate of only about 10%.

FDA Reports and Statistics

The FDA’s Adverse Event Reporting System (FAERS) has documented numerous cases of serious adverse events associated with Jentadueto and other DPP-4 inhibitors.

In the agency’s December 2017 announcement, the FDA noted that it was investigating reports of rhabdomyolysis in patients taking these medications, though no formal recommendations were issued at that time.

Regarding bullous pemphigoid, the FDA’s 2016 safety communication reported multiple cases associated with DPP-4 inhibitors, with 50% of these cases requiring hospitalization and one resulting in death. This prompted the agency to mandate new warnings on all DPP-4 inhibitor medications, including Jentadueto.

The FDA has also reviewed data from studies suggesting an increased risk of pancreatitis among users of incretin mimetics.

According to research published in Gastroenterology, these drugs may increase the risk of pancreatitis by six times compared to other diabetes medications.

Jentadueto Injuries & Side Effects

Jentadueto has been associated with several serious and potentially life-threatening side effects that have prompted legal action from affected patients and regulatory scrutiny.

• Pancreatic Cancer: Life-threatening malignancy with poor prognosis, often discovered in advanced stages when symptoms finally appear
• Thyroid Cancer: Abnormal cell growth in the thyroid gland, which may present as neck lumps, voice changes, and swallowing difficulties
• Bullous Pemphigoid: Rare autoimmune skin disease causing severe blistering that may require hospitalization and can be life-threatening in some cases
• Rhabdomyolysis: Serious muscle condition where damaged muscle tissue releases proteins into the bloodstream, potentially causing kidney damage
• Pancreatitis: Inflammation of the pancreas that can serve as a precursor to pancreatic cancer if left untreated

Jentadueto and Pancreatic Cancer

Pancreatic cancer originates in the pancreas, a large organ that manufactures enzymes that help digest food. The disease occurs when cells grow abnormally in the pancreas, and multiply to form tumors that can affect the ability of the organ to function properly.

In the initial stages of pancreatic cancer, a tumor may develop without symptoms, which means that the disease is often terminal when it is finally identified.

Jentadueto pancreatic cancer symptoms may include:

• dark urine
• clay-colored stools
• fatigue
• weakness
• jaundice
• loss of appetite
• weight loss
• nausea
• vomiting
• pain or discomfort in the upper part of the belly or abdomen
• back pain
• blood clots
• diarrhea
• indigestion

Bullous Pemphigoid

A rare skin disease called bullous pemphigoid that causes severe skin blistering has been linked to Jentadueto and all other diabetes drugs from the DPP-4 inhibitor class.

In October 2016, FDA asked manufacturers of DPP-4 inhibitors to add a bullous pemphigoid warning to their products’ labeling after the agency received multiple reports of the condition associated with the drugs. Each case had severe health outcomes, half of them required hospitalization and one died.

Thyroid Cancer

Thyroid cancer was first linked to incretin mimetic diabetes drugs by an animal study which found an association between the disease and Victoza.

The FDA required that a black box warning be placed on Victoza labels, and many have expressed concerns that the same warning should be placed on all other incretin mimetic labels as well.

Signs and symptoms of Jentadueto thyroid cancer may include:

• lumps / nodules in the neck
• hoarseness / changes to the voice
• swallowing or breathing problems
• pain in the throat / neck
• swollen lymph nodes in the neck
• cough not caused by other conditions
• enlarged thyroid gland

Related Articles:

• Actoplus Met Side Effects Lawsuit
• Tepezza Thyroid Eye Disease Lawsuit

Do You Qualify for a Jentadueto Lawsuit?

You may qualify for a Jentadueto lawsuit if:

• You were prescribed and took Jentadueto for type 2 diabetes
• You were diagnosed with pancreatic cancer, thyroid cancer, or bullous pemphigoid after taking the medication
• You were diagnosed with rhabdomyolysis or experienced severe muscle pain and weakness while taking Jentadueto
• You developed acute pancreatitis while taking the medication or shortly after discontinuing it
• You did not have a pre-existing diagnosis of the condition before starting Jentadueto

Evidence Required for a Jentadueto Lawsuit

• Medical records confirming your Jentadueto prescription and usage history
• Documentation of your diagnosis of pancreatic cancer, thyroid cancer, bullous pemphigoid, or other related condition
• Medical records establishing the timeline between Jentadueto use and onset of symptoms
• Prescription receipts or pharmacy records
• Documentation of medical treatments for your condition
• Expert medical testimony linking your condition to Jentadueto use

Damages You Can Recover

• Medical Expenses: Coverage for all treatment costs, including surgeries, hospital stays, medications, and ongoing care
• Lost Wages: Compensation for work missed due to illness and treatment
• Pain and Suffering: Damages for physical pain and emotional distress
• Loss of Quality of Life: Compensation for permanent changes to your lifestyle and capabilities
• Funeral Expenses: Coverage for funeral costs in wrongful death cases
• Punitive Damages: Additional compensation if the manufacturer showed gross negligence

Jentadueto Recall Information

While Jentadueto has not been subject to a complete market withdrawal or recall, the FDA has issued safety communications and required label changes for the entire class of DPP-4 inhibitors, including Jentadueto.

In October 2016, the FDA required manufacturers of all DPP-4 inhibitors, including Jentadueto, to add warnings about the risk of bullous pemphigoid to their product labeling.

This action came after the agency received multiple reports of this serious skin condition in patients taking these medications, with some cases requiring hospitalization and one resulting in death.

Which Diabetes Drugs are Incretin Mimetics?

In addition to Jentadueto, other incretin mimetics include:

• Byetta (exenatide)
• Bydureon (exenatide)
• Janumet (metformin and sitagliptin)
• Janumet XR (sitagliptin and metformin HCl extended-release) [3]
• Januvia (sitagliptin)
• Kazano (alogliptin and metformin)
• Kombiglyze XR (saxagliptin and metformin)
• Nesina (alogliptin)
• Onglyza (saxagliptin)
• Oseni (alogliptin and pioglitazone)
• Tradjenta (linagliptin)
• Victoza (liraglutide)

Statute of Limitations for Jentadueto Lawsuits

The statute of limitations for filing a Jentadueto lawsuit varies by state, typically ranging from 1 to 6 years from the date of injury or discovery of the injury.

Most states apply the “discovery rule,” meaning the statute of limitations begins when you discovered or reasonably should have discovered that your injury was caused by Jentadueto.

For example, if you were diagnosed with pancreatic cancer but didn’t immediately connect it to your Jentadueto use, the statute of limitations might begin when you learned of the potential link between the drug and your cancer, rather than on the date of diagnosis.

States with shorter limitations periods include:

• Kentucky (1 year)
• Louisiana (1 year)
• Tennessee (1 year)

States with longer limitations periods include:

• Maine (6 years)
• North Dakota (6 years)
• Minnesota (6 years)

Given these variations, consulting with an attorney promptly after being diagnosed with a condition potentially linked to Jentadueto is crucial to ensure your claim is filed within the applicable deadline.

FAQs

1. Can multiple people join together in a class action lawsuit against the makers of Jentadueto?

Yes, if multiple individuals have experienced similar adverse effects from using Jentadueto, they may be able to join together in a class action lawsuit. A class action can help consolidate the legal process, making it easier to demonstrate a pattern of harm caused by the drug and potentially leading to a more favorable outcome for all plaintiffs involved.

2. What should I do if I believe I’ve been harmed by Jentadueto?

If you believe you’ve been harmed by Jentadueto, you should consult with a healthcare professional to assess your health and ensure you receive appropriate care. Document your use of the medication, including any medical records and prescription information, and keep a record of your symptoms and treatments. Consulting with a lawyer who specializes in pharmaceutical litigation can help you explore your legal options.

3. How do I prove that Jentadueto caused my health problems?

To prove that Jentadueto caused your health problems, you will need medical records documenting your condition, evidence of your use of Jentadueto (such as prescription records), and potentially expert testimony linking the use of the medication to your health issues. A lawyer can help you gather and present this evidence effectively.

4. How long do I have to file a Jentadueto lawsuit?

The timeframe for filing a lawsuit varies by state, ranging from 1-6 years from injury discovery. Consulting with an attorney promptly is essential as the statute of limitations begins when you reasonably should have known your condition was related to Jentadueto use.

5. What is the difference between an individual lawsuit and a class action?

An individual lawsuit represents one person’s claims against the manufacturer, while a class action represents a group with similar injuries. Individual lawsuits may be more appropriate for unique or severe injuries, while class actions are efficient for addressing common injuries among multiple plaintiffs.

6. How much compensation could I receive from a Jentadueto lawsuit?

Compensation varies widely based on injury severity, medical costs, lost income, and pain and suffering. Cases involving permanent disability or fatal conditions like pancreatic cancer typically result in higher settlements than those involving conditions with better treatment outcomes.

7. Should I stop taking Jentadueto if I’m considering a lawsuit?

Never discontinue any medication without consulting your healthcare provider first. Abruptly stopping diabetes medication can cause serious health complications. Discuss your concerns with your doctor, who can recommend alternative treatments if appropriate.

See all dangerous drugs lawsuits we’ve taken on.

Take Action Now: Time-Sensitive Legal Claims

Time is limited to pursue legal action for injuries related to Jentadueto. Most states have a statute of limitations of only 2-3 years from the date you discovered your injury was related to the medication, with some states allowing as little as 1 year to file a claim.

At Schmidt & Clark, LLP, we offer:

• Free, confidential consultations to evaluate your case
• No upfront costs or attorney fees
• Payment only if we win your case

Free Confidential Case Evaluation: Again, if you got pancreatic cancer after taking Jentadueto, you should contact our law firm immediately. You may be entitled to compensation by filing a class action suit and our lawyers can help.

References

1. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm579459.htm

2. http://www.gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract

3. https://www.fda.gov/downloads/Drugs/DrugSafety/UCM291878.pdf